Kane Biotech, iCo Therapeutics Inc. Selected as Among Canada's Top 10(TM) Life Sciences Companies
Kane Biotech Inc., a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms, and iCo Therapeutics Inc. ia Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications have been selected as one of the 2010 winners of the annual Canada's Top 10(TM) Competition. The award was announced on October 13th in Montreal. Top 10(TM) winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. The panel can be viewed at http://www.topcanadiancompanies.ca/jury/lifesciences.html.
"Kane is honored to have been selected to receive this award," stated Kane Biotech President & CEO, Gord Froehlich. "Independent validation from a jury of experienced venture capitalists that posses a strong track record of success in the life sciences industry is highly valuable. We are proud to be included among such a respected, high-profile group of companies."
Competition winners participate in a series of investment forums in select cities across the U.S. Developed together with key sponsors, partners and the Canadian consulates in each city, the forums expose the Top 10(TM) companies to an exclusive group of top tier United States and Canadian investors, venture capitalists, licensing executives and potential strategic partners in a series of invitation only events.
Current winners and alumni have secured over $600 million in disclosed venture capital financing since being selected for this award.
"I continue to be impressed by the quality of companies that I see coming out of Canada," says Bernhardt Zeisig, Partner, Cycle Ventures LLC. "Because of programs like this, I get to review companies that I would normally not see. This competition is an effective way to put companies in front of investors like us."
About the Canada's Top 10(TM) Competition
The vision for the Canada's Top 10(TM) is to be Canada's premier investment oriented competition by selecting the best potential investments in Canada for investors and providing high value added services to companies to increase their chances of success, both as they source investment and as they grow and compete in the global environment. Since its inception, competition alumni have secured more than $600M in venture capital financing.
Competition winners may participate in a series of investment forums in select cities across the U.S. Developed together with key sponsors, partners and the Canadian consulates in each city, the forums expose the Top 10(TM) companies to an exclusive opportunity to present to top tier U.S. and Canadian venture capitalists, licensing executives and potential strategic partners in a series of invitation only events.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products to prevent and remove biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and are involved in approximately 80% of all human bacterial infections. The healing of chronic wounds alone costs the United States health care system $20 Billion per year.
Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase II for the treatment of DME, iCo-008; a product with Phase II clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: www.icotherapeutics.com
No comments:
Post a Comment